NICE says no to Celgene's myeloma drug Imnovid; Sucampo, Takeda extend Amitiza pact;

> The U.K.'s cost-effectiveness watchdog has issued preliminary draft guidance not recommending Celgene's ($CELG) multiple myeloma treatment Imnovid. More

> Sucampo and Takeda have extended their licensing agreement for constipation drug Amitiza. Release

> ViiV Healthcare has won approval for HIV pill Triumeq in Canada. Release

> Scotland has recommended Novartis' ($NVS) Gilenya for patients with a severe form of relapsing multiple sclerosis. Report

> Retrophin has agreed to divest ketamine, Syntocinon Nasal Spray, and Vecamyl to Turing Pharmaceuticals. Release

And Finally... Pfizer ($PFE) has joined up with leaders in the breast cancer community to expand the breast cancer dialogue to include metastatic breast cancer. More

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.